Epitan plans AIM listing
Thursday, 31 March, 2005
Melbourne's Epitan is planning to raise up to 15 million pounds (AUD$37 million) in a flotation on London's AIM stock market. EpiTan focuses on dermatology and its main product, Melanotan, helps treat sunburn injury.
The company said its London flotation would raise money to fund further development of Melanotan and increase its international profile. EpiTan is already listed on the Australian stock exchange.
"I am delighted to be able to introduce EpiTan to UK investors, particularly as we expect Europe to be a key market for our lead development product, Melanotan," said chief executive Iain Kirkwood.
Trading in the shares on AIM is due to begin in May. Investment bank Teather & Greenwood is the broker and adviser on the flotation.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
